VGT vs XBI

Vanguard Information Technology ETF vs SPDR S&P Biotech ETF

Quick take
  • VGT has the lower expense ratio at 0.09% vs 0.35% for XBI.
  • VGT pays a higher dividend yield (0.37%).

Side-by-side metrics

MetricVGTXBI
Expense ratio
Annual fee. Lower is better.
0.09%0.35%
Dividend yield
Trailing 12-month yield.
0.37%0.34%
AUM
Assets under management — bigger funds are typically more liquid.
$146.53B$8.30B
YTD return
16.40%12.92%
1-year return
3-year return
Annualized.
5-year return
Annualized.
10-year return
Annualized.
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
1.291.09
P/E ratio
39.12
Last price
$109.50$133.66
Inception
Issuer
VanguardState Street

VGT top holdings

Top holdings · VGT
NVDANVIDIA Corp18.52%
AAPLApple Inc15.85%
MSFTMicrosoft Corp10.20%
AVGOBroadcom Inc4.38%
MUMicron Technology Inc2.02%
AMDAdvanced Micro Devices Inc1.75%
PLTRPalantir Technologies Inc Ordinary Shares - Class A1.74%
CSCOCisco Systems Inc1.65%
AMATApplied Materials Inc1.47%
LRCXLam Research Corp1.45%
Sector breakdown · VGT
Basic Materials0.0%
Technology98.5%
Communication Services0.5%
Financial Services0.5%
Industrials0.5%
Healthcare0.0%

XBI top holdings

Top holdings · XBI
APLSApellis Pharmaceuticals Inc1.87%
RVMDRevolution Medicines Inc Ordinary Shares1.65%
TVTXTravere Therapeutics Inc Ordinary Shares1.62%
ARWRArrowhead Pharmaceuticals Inc1.44%
TWSTTwist Bioscience Corp1.42%
SMMTSummit Therapeutics Inc Ordinary Shares1.40%
ALKSAlkermes PLC1.38%
TGTXTG Therapeutics Inc1.37%
MDGLMadrigal Pharmaceuticals Inc1.36%
BEAMBeam Therapeutics Inc1.32%
Sector breakdown · XBI
Financial Services0.2%
Healthcare99.8%

About VGT

VGT (Vanguard Information Technology ETF) is US technology sector stocks. Managed by Vanguard, the fund carries $146.5B in assets under management, an expense ratio of 0.09%, a dividend yield of 0.37%. Its largest holding is NVIDIA Corp (NVDA), which represents 18.5% of the portfolio. Basic Materials is the fund's largest sector exposure at 0.0%.

About XBI

XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.